University of Thessaly (UTH)
Μέτρηση ενδοθηλίνης-1 (ET-1) και αγγειοδραστικού ενδοθηλιακού αυξητικού παράγοντα (VEGF) σε συνδυασμό με τη μέτρηση αιμάτωσης του ήπατος (DPI) στους ασθενείς με καρκίνο παχέος εντέρου
Abstract
dc:descriptionColorectal cancer is one of the leading causes of cancer mortality worldwide. The liver is the most common site of colorectal metastases. Among patients diagnosed with colorectal cancer, 15-25% present with hepatic disease, while almost half of those subjected to therapeutic surgical treatment develop liver metastases during the first 2 years postoperatively. The most commonly used imaging modalities of the liver ie US, CT and MRI, are limited from an inherent to each technique level of differentiation capability between normal and pathologic tissue. On the other hand, it is known that perfusion changes of the liver are detected in the presence of even very small metastatic lesions. A way of measuring these changes is the calculation with color Doppler of hepatic blood flow (comprised of hepatic artery and portal vein flow) and the estimation of the ratio of arterial flow to the total liver flow, defined as Doppler Perfusion Index. It has been suggested that DPI values >0.3 correlate not only with unequivocal liver disease but also with micrometastatic one and worse colorectal cancer patients prognosis.Endothelin-1 (ET-1), is a potent vasoconstricting peptide- 100 times more powerful than norepinephrin in a molar basis, and there is increasing evidence of its role in carcinogenesis, colorectal cancer included. ET-1 acts by binding to 2 distinct receptors: ET-A (ETAR) and ET-B (ETBR), which belong to the G protein- coupled receptor subtype (GPCRs). Their activation produces multiple effects, as the coupling with G proteins leads to induction of several intracellular pathways, and is the subject of intense research. Moreover, this increasingly important role of ET-1 axis in cancer progression has led, during the recent years, to an effort of ET-1 inhibition. Worthmentioning is the development of ETR antagonists, such as ETAR inhibitors ABT-627(atrasentan) and ZD4054, that are currently being tested in clinical trials in ovarian, breast and castration resistant metastatic prostate cancer. Under investigation is also the relation between ET-1 and VEGF, a known angiogenic factor, the inhibition of which is used in colorectal and other anticancer treatment.The present study included 39 patients with a diagnosis of colorectal carcinoma, of whom 20 were female and 19 male, with a mean age of 71.1 years (range, 43-84 years), who were surgically treated in the University Department of Surgery, University of Thessaly, School of Medicine, Greece from February 2003 to September 2006. In 29 patients DPI measurement was conducted preoperatively. Tumor specimens from all 39 patients were processed for immunohistochemical analysis for ET-1 and its receptors ETAR and ETBR. Additionally, from 10 patients a second tumor sample was snap-frozen and stored at -70oC while adjacent normal tissue was included from each case examined. Those samples were processed for Western Blot analysis. From these patients, 3 blood samples were also collected: intraoperatively, from mesenteric circulation adjacent to the tumor site (sample A) and from peripheral circulation before the tumor resection (sample B), and 24h postoperatively from peripheral circulation (sample C). These samples were centrifugated and serum was stored at -70oC. All samples were processed for ET-1 and VEGF enzyme immunoassay ELISA. After a mean time of 60 months follow-up, statistical analysis of the results and the overall and 5-year disease free survival was conducted. Finally, four colon carcinoma cell lines including HT-29, HT-116, COLON 205, and SW-48 were processed for Western Blot analysis. The measured DPI values from the aforementioned 29 patients did not correlate nor with Duke’s stage neither with overall and 5-year disease free survival, when the suggested from previous reports cut-off point of 0.3 was used. However, worthmentioning finding is the statistically significant correlation of DPI with overall survival when the median observed value of 0.2 was used as a cut-off point. More data on a larger number of patients are needed to evaluate this finding.ET-1 was immunohistochemically expressed by tumor cells at a variable level in all 39 cases tested, while the adjacent normal mucosa was negative for ET-1 expression. Also, cancerous tissue expressed predominantly ETAR and not ETBR with the latter being detected mostly in normal colonic mucosa. Interestingly, strong ETAR expression was observed in the deeper infiltrating areas at the periphery of neoplastic tissue in 26 of 37 (70.3%) cases of colon carcinoma. Strong ETAR expression in the tumor areas of the deep margins significantly correlated with tumor stage including Dukes (p=0.031, chi-square test) and Asler-Coller (p=0.027, chi-square test).This association is even stronger if combined Astler – Coller A and B1 stages are compared to combined more advanced (B2, C1, C2, D) stages (p=0.005). No statistically significant correlation was found between strong ET-1 or ETAR expression and DPI values. Similarly, in 30 of 39 patients with complete follow up data at 5 years, no significant correlation between ET-1 or ETAR expression and recurrence or overall survival was found.Western blot analysis performed in paired normal and tumor patient samples showed substantially higher levels of ET-1 and ETAR proteins in tumor tissues as compared to normal tissues. ETBR levels were very low or absent in these tumor samples. Similarly, ET-1 protein as well as ETAR were detected at a high level in all four colon carcinoma cell lines tested while ETBR levels were very low or even undetectable by Western blot analysis in this in vitro system. Also, statistically significant differences were found between the preoperative measurements of ET-1 either in the mesenteric circulation (patient group A) or the peripheral blood (patient group B) and the postoperative peripheral ones (Patient group C) (A vs C, p-value: 0,03 and B vs. C, p-value: 0,01, by Mann-Whitney test). On the contrary, no significant difference was found in VEGF values before and after tumor resection.In conclusion, expression of ET-1 and ETAR was demonstrated both in the in vitro systems and in colorectal cancer tissues studied. This expression was proved more intense in advanced disease, while it is possible that high ET-1 axis expression in cellular level corresponds to elevated circulation levels. In this cohort of patients however, ET-1 does not seem to play a role in liver perfusion changes associated with metastatic disease nor does it seem to share a similar pattern of expression with the angiogenic factor VEGF. These findings are preliminary and more data are needed before firm conclusions can be drawn.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Liakou, Paraskevi
- Λιάκου, Παρασκευή
Subjects
dc:subject × 12- Ενδοθηλίνη-1 (ΕΤ-1)
- Αγγειοδραστικός ενδοθηλιακός αυξητικός παράγοντας
- Δείκτης αιμάτωσης ήπατος
- Καρκίνος παχέος εντέρου
- Endothelin-1
- Vascular endothelial growth factor (VEGF)
- Doppler perfusion index (DPI)
- Colorectal cancer
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27588